Linear IgA bullous dermatosis treated with rituximab
- PMID: 30671527
- PMCID: PMC6330365
- DOI: 10.1016/j.jdcr.2018.11.004
Linear IgA bullous dermatosis treated with rituximab
Keywords: LABD, Linear IgA bullous dermatosis; MMF, mycophenolate mofetil; autoimmune blistering disease; linear IgA bullous dermatosis; rituximab.
Figures
References
-
- Bernard P., Vaillant L., Labeille B. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131:48–52. - PubMed
-
- Paul C., Wolkenstein P., Prost C. Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol. 1997;136:406–411. - PubMed
-
- Albers L.N., Zone J.J., Stoff B.K., Feldman R.J. Rituximab Treatment for recalcitrant dermatitis herpetiformis. JAMA Dermatol. 2017;153:315–318. - PubMed
-
- Lozinski A., Baum S., Sagi L., Volkov A., Trau H., Barzilai A. [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders] Harefuah. 2012;151:562–565. 606. - PubMed
-
- Vodegel R.M., de Jong M.C.J.M., Pas H.H., Jonkman M.F. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol. 2002;47:919–925. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous